Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of irritability in pervasive developmental disorders.
Child Adolesc Psychiatr Clin N Am. 2008 Oct; 17(4):739-52, vii-viii.CA

Abstract

Children and adolescents diagnosed with autism and related pervasive developmental disorders (PDDs) often sustain irritability, including aggression, self-injurious behavior, and tantrums. Research to date supports the use of the atypical antipsychotics as a first-line pharmacologic treatment for this target symptom domain in PDDs. Currently, the atypical antipsychotic risperidone is the only medication approved by the US Food and Drug Administration for irritability in youth with autism. Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group.

Authors+Show Affiliations

Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202-5200, USA. kstigler@uipui.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18775367

Citation

Stigler, Kimberly A., and Christopher J. McDougle. "Pharmacotherapy of Irritability in Pervasive Developmental Disorders." Child and Adolescent Psychiatric Clinics of North America, vol. 17, no. 4, 2008, pp. 739-52, vii-viii.
Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):739-52, vii-viii.
Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America, 17(4), 739-52, vii-viii. https://doi.org/10.1016/j.chc.2008.06.002
Stigler KA, McDougle CJ. Pharmacotherapy of Irritability in Pervasive Developmental Disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):739-52, vii-viii. PubMed PMID: 18775367.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of irritability in pervasive developmental disorders. AU - Stigler,Kimberly A, AU - McDougle,Christopher J, PY - 2008/9/9/pubmed PY - 2008/12/17/medline PY - 2008/9/9/entrez SP - 739-52, vii-viii JF - Child and adolescent psychiatric clinics of North America JO - Child Adolesc Psychiatr Clin N Am VL - 17 IS - 4 N2 - Children and adolescents diagnosed with autism and related pervasive developmental disorders (PDDs) often sustain irritability, including aggression, self-injurious behavior, and tantrums. Research to date supports the use of the atypical antipsychotics as a first-line pharmacologic treatment for this target symptom domain in PDDs. Currently, the atypical antipsychotic risperidone is the only medication approved by the US Food and Drug Administration for irritability in youth with autism. Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group. SN - 1056-4993 UR - https://www.unboundmedicine.com/medline/citation/18775367/Pharmacotherapy_of_irritability_in_pervasive_developmental_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-4993(08)00046-1 DB - PRIME DP - Unbound Medicine ER -